Similarly, there is little evidence that dupilumab, which decreases tissue eosinophilia and blocks IL-4 and IL-13 signaling, adversely affects tissue repair, despite a growing body of evidence pointing to the importance of eosinophil secretion of IL-4 in this process109. The gene discussed is IL4; the disease is Increased total eosinophil count.